Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
The EXTREME registry: Titanium-nitride-oxide coated stents in small coronary arteries
Catheterization and Cardiovascular Interventions, Volume 76, No. 2, Year 2010
Notification
URL copied to clipboard!
Description
Objectives: We sought to explore the immediate results of Titan2® stent implantation in small coronary arteries, as well as the incidence of major adverse cardiac events (MACE) at six months follow-up. Background: The safety of Titan2® stent has been confirmed in several studies in real-life unselected populations. Methods: We enrolled 311 consecutive patients admitted for percutaneous intervention for at least one significant (50%) de novo lesion in a native small coronary artery (2.0-2.75 mm). All lesions were treated with Titan2® stent implantation. Patients were prospectively followed up for at least six months. The primary endpoint was MACE at six months follow-up [death, myocardial infarction (MI), or target vessel revascularization (TVR)]. Secondary endpoints included angiographic and clinical procedural success, in-hospital MACE, target lesion revascularization (TLR) during follow-up, and stent thrombosis. Results: The mean age was 67.3 ± 10.9 years (65.9% males). A total of 356 Titan2® stents were implanted in 353 lesions. Angiographic and clinical procedural success was achieved in 344 (97.5%) patients. No case of in-hospital MACE or acute stent thrombosis was reported. Clinical follow-up was completed for an average of 8 ± 2 months. Two patients (0.7%) died, and 6 (2.1%) developed MI. TLR was performed in 12 (4.2%) and TVR in 16 (5.5%) patients, all were clinically driven. Cumulative MACE occurred in 20 (6.9%) patients. One patient suffered subacute stent thrombosis, but no late stent thrombosis. Conclusions: Titan2® stent implantation in small coronary arteries achieves excellent immediate outcome, with a low incidence of MACE at mid-term follow-up. © 2010 Wiley-Liss, Inc.
Authors & Co-Authors
Valdesuso, Raúl
Spain, Murcia
Hospital Clínico Universitario Virgen de la Arrixaca
Karjalainen, Pasi Paavo
Finland, Pori
Satakunta Central Hospital
García, Joan
Spain, Barcelona
Hospital de la Santa Creu I Sant Pau
Díaz, José
Spain, Huelva
Clinica de Coloproctologia Hospital Juan Romon Jimenez
Portales, Javier Fernández
Spain, Caceres
Hospital San Pedro de Alcantara
Masotti, Mónica
Spain, Barcelona
Hospital Clinic Barcelona
Picó, Francisco
Spain, Cartagena
Hospital Santa Maria Del Rosell
Serra, Antonio
Spain, Barcelona
Hospital Del Mar
Burgos, José Moreu
Spain, Toledo
Complejo Hospitalario de Toledo
Insa, Luis
Spain, Valencia
Hospital Clinico Universitario de Valencia
Mauri, Fina
Spain, Badalona
Hospital Universitari Germans Trias I Pujol
Collado, Javier Rodriguez
Spain, Salamanca
Hospital Clínico Universitario de Salamanca
Nammas, Wail M.
Egypt, Cairo
Faculty of Medicine - Ain Shams University
Statistics
Citations: 13
Authors: 13
Affiliations: 13
Identifiers
Doi:
10.1002/ccd.22474
ISSN:
15221946
e-ISSN:
1522726X
Research Areas
Health System And Policy
Noncommunicable Diseases
Study Design
Randomised Control Trial
Cohort Study